Eli Lilly and Co (LLY) : Primecap Management Coca scooped up 102,526 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 57,756,918 shares of Eli Lilly and Co which is valued at $4,408.6 Million.Eli Lilly and Co makes up approximately 4.95% of Primecap Management Coca’s portfolio.
Other Hedge Funds, Including , Ropes Wealth Advisors boosted its stake in LLY in the latest quarter, The investment management firm added 1,560 additional shares and now holds a total of 4,950 shares of Eli Lilly and Co which is valued at $377,834. Eli Lilly and Co makes up approx 0.17% of Ropes Wealth Advisors’s portfolio.Wms Partners reduced its stake in LLY by selling 183 shares or 3.12% in the most recent quarter. The Hedge Fund company now holds 5,675 shares of LLY which is valued at $433,173. Eli Lilly and Co makes up approx 0.06% of Wms Partners’s portfolio.Advantus Capital Management Inc boosted its stake in LLY in the latest quarter, The investment management firm added 584 additional shares and now holds a total of 94,834 shares of Eli Lilly and Co which is valued at $7.2 Million. Eli Lilly and Co makes up approx 0.22% of Advantus Capital Management Inc’s portfolio.Quantitative Investment Management boosted its stake in LLY in the latest quarter, The investment management firm added 40,600 additional shares and now holds a total of 85,400 shares of Eli Lilly and Co which is valued at $6.4 Million. Eli Lilly and Co makes up approx 0.30% of Quantitative Investment Management’s portfolio.Ashburton (jersey) Ltd boosted its stake in LLY in the latest quarter, The investment management firm added 4,815 additional shares and now holds a total of 90,785 shares of Eli Lilly and Co which is valued at $6.9 Million. Eli Lilly and Co makes up approx 2.40% of Ashburton (jersey) Ltd’s portfolio.
Eli Lilly and Co opened for trading at $74.79 and hit $75.54 on the upside on Friday, eventually ending the session at $74.81, with a gain of 0.67% or 0.5 points. The heightened volatility saw the trading volume jump to 46,89,174 shares. Company has a market cap of $82,578 M.
On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.